Larimar director granted 55,150 stock options
Larimar Therapeutics director Thomas Edward Hamilton received a grant of stock options covering 55,150 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Larimar Therapeutics director Thomas Edward Hamilton received a grant of stock options covering 55,150 shares of common stock. The options have an exercise price of $3.33 per share and expire on May 19, 2036. They vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued service on the board. Following this grant, he holds 55,150 options directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 55,150 | $0.00 | $0.00 |
Footnotes (1)
- F1. The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
Grant, award, or other acquisition financial
exercise price financial
Board of Directors financial
vest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Larimar Therapeutics (LRMR) report for Thomas Edward Hamilton?
What are the key terms of the 55,150 stock options granted at Larimar Therapeutics (LRMR)?
When do Thomas Edward Hamilton’s Larimar (LRMR) stock options vest?
How many Larimar (LRMR) options does Thomas Edward Hamilton hold after this grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.